BACKGROUND AND AIMS: Lysosomal acid lipase deficiency is characterized by hepatomegaly and dyslipidaemia, which can lead to cirrhosis and premature atherosclerosis. Sebelipase alfa is an approved recombinant human lysosomal acid lipase. In an open-label extension study of adults with lysosomal acid lipase deficiency (LAL-CL04), sebelipase alfa treatment for 1 year reduced serum transaminase levels and liver fat content and improved serum lipid levels. METHODS: Final data from LAL-CL04 are reported herein for patients who received sebelipase alfa infusions (1.0 or 3.0 mg/kg every other week) for up to 5 years. RESULTS: Of 8 patients enrolled, 7 received sebelipase alfa for 224-260 weeks; 1 was lost to follow-up. Median baseline levels of alanine aminotransferase and aspartate aminotransferase (81.5 and 50.0 U/L, respectively) were decreased through the end-of-study visit (54.0 and 34.0 U/L). Median low-density lipoprotein cholesterol decreased from 113 to 78 mg/dL, total cholesterol decreased from 171 to 132 mg/dL, and high-density lipoprotein cholesterol increased from 37 to 42 mg/dL. Most treatment-emergent adverse events were nonserious (99%), mild/moderate (98%) and unrelated to sebelipase alfa (87%); no patient discontinued as a result of treatment-emergent adverse events. One patient had 2 serious treatment-emergent adverse events (cholecystitis and cholelithiasis; assessed as unlikely related to sebelipase alfa). Two patients had 20 nonserious infusion-associated reactions in weeks 6-38; all were manageable. One patient tested positive for antidrug antibodies (single occurrence). CONCLUSIONS: Sebelipase alfa was well tolerated and improved serum transaminase and lipid levels for up to 5 years in adults with lysosomal acid lipase deficiency. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov record NCT01488097.

Advanced Therapies Program and Gene Therapy Center University of Minnesota Minneapolis MN USA

Alexion Pharmaceuticals Inc Boston MA USA

Department for Metabolic Diseases Children's Clinic General Faculty Hospital and 1st Faculty of Medicine of Charles University Prague Prague Czech Republic

Department of Endocrinology and Metabolic Medicine Salford Royal Foundation NHS Trust Salford UK

Department of Genetics and Genomic Sciences and Department of Medicine Icahn School of Medicine at Mount Sinai New York NY USA

Department of Inherited Metabolic Diseases Hôpital Necker Enfants Malades Paris France

Department of Medicine University of California San Francisco San Francisco CA USA

See more in PubMed

Grabowski GA, Charnas L, Du H. Lysosomal acid lipase deficiencies: the Wolman disease/cholesteryl ester storage disease spectrum In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, eds. Metabolic and Molecular Bases of Inherited Disease, 8th ed New York, NY: McGraw‐Hill; 2012.

Rader DJ. Lysosomal acid lipase deficiency ‐ a new therapy for a genetic lipid disease. N Engl J Med. 2015;373(11):1071‐1073. PubMed

Reiner Ž, Guardamagna O, Nair D, et al. Lysosomal acid lipase deficiency–an under‐recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis. 2014;235(1):21‐30. PubMed

Bernstein DL, Hulkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013;58(6):1230‐1243. PubMed

Hamilton J, Jones I, Srivastava R, Galloway P. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2012;413(15–16):1207‐1210. PubMed

Valayannopoulos V, Mengel E, Brassier A, Grabowski G. Lysosomal acid lipase deficiency: expanding differential diagnosis. Mol Genet Metab. 2017;120(1–2):62‐66. PubMed

Lukacs Z, Barr M, Hamilton J. Best practice in the measurement and interpretation of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2017;471:201‐205. PubMed

Burton BK, Deegan PB, Enns GM, et al. Clinical features of lysosomal acid lipase deficiency ‐ a longitudinal assessment of 48 children and adults. J Pediatr Gastroenterol Nutr. 2015;61(6):619‐625. PubMed PMC

Gasche C, Aslanidis C, Kain R, et al. A novel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin. J Hepatol. 1997;27(4):744‐750. PubMed

Bernstein DL. Lysosomal acid lipase deficiency is associated with premature death in children and adults [abstract]. Mol Genet Metab. 2018;123(2):S24.

Bernstein DL, Lobritto S, Iuga A, et al. Lysosomal acid lipase deficiency allograft recurrence and liver failure‐ clinical outcomes of 18 liver transplantation patients. Mol Genet Metab. 2018;124(1):11‐19. PubMed

Alexion Europe SAS . Kanuma® (sebelipase alfa) [summary of product characteristics]. Rueil‐Malmaison, France: Alexion Europe; 2015.

Alexion Pharmaceuticals, Inc . Kanuma® (sebelipase alfa) [package insert]. New Haven, CT: Alexion Pharmaceuticals Inc.; 2015.

Balwani M, Breen C, Enns GM, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology. 2013;58(3):950‐957. PubMed PMC

Valayannopoulos V, Malinova V, Honzík T, et al. Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J Hepatol. 2014;61(5):1135‐1142. PubMed PMC

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495‐1499. PubMed

Burton BK, Balwani M, Feillet F, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med. 2015;373(11):1010‐1020. PubMed

Burton BK, Consuelo Sanchez A, Kostyleva M, Allen K, Friedman M, Martins AM. Long‐term benefit of sebelipase alfa over 96 weeks in a diverse population of children and adults with lysosomal acid lipase deficiency [abstract 817]. Hepatology. 2017;66(suppl):437A.

See more in PubMed

ClinicalTrials.gov
NCT01488097